BostonGene to Participate in Pathology Visions 2024, Driving Collaborative Advancements in Digital Pathology and Regulatory Science
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in Pathology Visions, taking place November 3-5, 2024, at the Hyatt Regency in Orlando, Florida. Pathology Visions brings together digital pathology experts and professionals to explore current and practical applications and future innovations shaping the field. This event offers a unique opportunity for immersive learning, featuring expert insights, groundbreaking research and exceptional networking opportunities.
During the event, Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, will moderate a panel session, “Advancing Regulatory Science in Digital and Computational Pathology: A Collaborative Dialogue.” This session, scheduled for Tuesday, November 5, will bring together industry, academia and regulatory bodies to drive advancements in regulatory science and accelerate digital pathology adoption in the U.S. It will showcase recent developments and offer diverse perspectives on these advancements.
“Pathology Visions offers a dynamic platform for driving progress in digital pathology. The conference brings together diverse experts from around the world," said Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene. "I’m excited to moderate the discussion on advancing regulatory science. Collaborative efforts between industry, academia, and regulatory bodies are essential to accelerate digital pathology adoption in the U.S. This conference is a valuable opportunity to share insights, explore innovative solutions and shape the future of pathology for better patient care.”
For more information, visit the Pathology Visions website.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
